| Detailed information |
|---|
| CancerLivER ID | 2351 |
| Biomarker | CYP3A5P2 |
| Biomarker Name/Symbol (given in Publication) | CYP3A5P2 |
| Biomolecule | RNAs |
| Subject | Human |
| Degree of Validity | Differentially expressed in HCCs with PVI in comparison with HCCs without PVI; but not validated on independent dataset |
| Experimental Condition | HCC with PVI v/s HCC without PVI |
| Cancer type | Hepatocellular carcinoma |
| Regulation | Downregulated in HCCs with PVI in comparison with HCCs without PVI (with Fisher ratio 1.21) |
| Level of significance | p < 0.05 |
| Source | Tissue |
| PMID | 17088983 |
| Type of Biomarker | Prognostic |
| Pathway | Detoxification system |
| Cohort | 14 HCCs with PVI and 21 HCCs without PVI. |
| Sensitivity | NA |
| Specificity | NA |
| Accuracy | NA |
| AUC | NA |
| Disease | HCV associated HCC |
| Year of Publication | 2006 |
| Clinical trial | NO |
| Clinical trial (NCT Number) | NA |